ESMO Virtual Mentorship Programme
1:11
Пікірлер
@MarceloRojasRamirez-ki4wj
@MarceloRojasRamirez-ki4wj 13 күн бұрын
Accurate questions, accurate answers. This is one of those non-popular brilliant youtube videos that actually sum up a topic in a very precise way.
@RoyalNebesnik
@RoyalNebesnik 2 ай бұрын
82797 Abigail Ranch
@ryanweaver962
@ryanweaver962 4 ай бұрын
when we see vitamins and various crafting of health gain more understanding and market power... the feedback loops into populations and methodologies and value... lead reimbursements.... the interdisciplinary work and rights of individuals and groups are paramount to effective better.
@MichaelAlucard
@MichaelAlucard 6 ай бұрын
Aren't you palty Turcios
@marcofranzosi8825
@marcofranzosi8825 8 ай бұрын
Loud music and thick French accent made this video so tough to follow
@stefaniecolonius4780
@stefaniecolonius4780 9 ай бұрын
🎶🎵 On Wisconsin 🎵🎶 •Is there an update on the roadmap? 🤔 •Law + Healthcare 🙌🏼🙏🏼 •GAPRI Strategy 🎉 •Hospice or Home Healthcare 🤔 •Local Fellowship 🫂 🙏🏼 •Amen Juice from The Biblical Nutritionist ❤️🥳 •Medical Mushrooms • (20) Hydrocodone is not enough and that's even if it's given as a placebo. 🤯 Thank you for this video 11 years ago. Cancer Pain is a real hell experience. In advance, Id like to thank Jesus Christ for the healing that's coming. 🙏🏼 ❤ Minister Stefanie Colonius, MMHCA 💖 John 3:16 KJV 💖
@rittenbrake1613
@rittenbrake1613 2 жыл бұрын
Thank you for the teaching
@jessicakohgadai3852
@jessicakohgadai3852 2 жыл бұрын
I would love if you can go to Peru and treat my father from thymona cancer . He keeps getting plural in his system . 3 times water already . :(
@Matthouin
@Matthouin Жыл бұрын
I’m looking for thymoma medicine like pill form to slow the growth . I can’t find anything type of therapy’s like that . Iv lost my left lung half my diaphragm within two years of my diagnosis ! I’m only 44
@zack.dar40
@zack.dar40 7 ай бұрын
​@Matthouin Matt have you looked at Coimbra protocol?
@1980yadalam
@1980yadalam 2 жыл бұрын
very good
@hoahuynh5002
@hoahuynh5002 3 жыл бұрын
Very good and funny videos bring a great sense of entertainment!
@guilost4943
@guilost4943 3 жыл бұрын
CAN YOU PPST 1 HOU 40 MINUTES CRONIC PAIN HOW OPIATES WORKS MOST CONUN DOSAGES ON CRONIC PAIN PACIENTS OUTSIDE CANCER THIS MOST DISSEASES OPIATES USE MOST ARTITHS OSTEOARTRITHS FYBROMYALGIA LOW BACK PAIN BONE DISSEASES ETC A FULL OPIATES CRONIC PAIN PROGAM? I suffer 24 hours pain just 28 years so sad dont want continue living aoo much suffering
@matovicmmilan
@matovicmmilan 3 жыл бұрын
Do you have access to morphine or similar analgesic where you're living?
@esragbilir
@esragbilir 3 жыл бұрын
Thank you Prof Colombo
@dariotrapani1966
@dariotrapani1966 3 жыл бұрын
Immense, doc!
@connor6267
@connor6267 3 жыл бұрын
very cool
@vivianmasia2992
@vivianmasia2992 4 жыл бұрын
Thank you. This has helped a lot
@iangarth6174
@iangarth6174 4 жыл бұрын
A complex subject described simply! Thanks mates for a great video.
@neuruza
@neuruza 4 жыл бұрын
I totally agree. I am a young mother and for me being able to take part in virtual meetings is sometimes much more challenging than previous, when I had to travel. I hope it will change
@neuruza
@neuruza 4 жыл бұрын
That's true. I am 31 year old woman and a mother of 4 year old boy. I have stayed at home since March this year because of pandemic. In January i had planed to prepare my PhD thesis and some papers during this few months and imagine how many things I could not do because of this situation. I hope I will continue my work and development in the near future, however this situation had a huge impact on my career. Thank you for this video. Now I feel that somewhere in the world are great people understanding my situation. Best regards. Zuzanna
@ekaterinaevdo934
@ekaterinaevdo934 4 жыл бұрын
Thanks a lot! Also really grateful for ESMO colorectal cancer preceptorship in 2019, still studying and its still helpful
@dr.enasaboubakrelkhoulydro4703
@dr.enasaboubakrelkhoulydro4703 4 жыл бұрын
Valuable talk
@safimohammed8583
@safimohammed8583 5 жыл бұрын
As usual, You are SO GREAT our Prof
@AmitSehrawatdr
@AmitSehrawatdr 7 жыл бұрын
Essential series is really a good initiative by ESMO, it must b made available in all sub specialities
@jacksalvatierra7959
@jacksalvatierra7959 7 жыл бұрын
wonderful.....
@shariqqayyum9660
@shariqqayyum9660 7 жыл бұрын
nice work .she is been a great researcher..
@johnbates2709
@johnbates2709 7 жыл бұрын
This is a great review, thank you. Great to see such a clear review of a complex rapidly evolving field that identifies the most salient areas.
@MuhammadKhalid-ni9fj
@MuhammadKhalid-ni9fj 8 жыл бұрын
excellent symposium
@nicademus8
@nicademus8 10 жыл бұрын
Its nice that these new targeted drugs (BRAF inhibitors, MEK inhibitors) exist. But patient should NEVER be given them as a first-line therapy for metastatic melanoma. These drugs cannot cause complete and durable regressions of the tumors; only immunotherapies can do that. Patients should try a checkpoint inhibitor (anti-CTLA-4, anti-PD1), high dose interleukin-2, or adoptive cell transfer of infiltrating lymphocytes first. If one or more of these immune therapy attempts fail, then targeted inhibitors (BRAF, MEK) are a good fallback. These drugs can give a patient a few extra months to get their affairs in order and take a nice vacation before the melanoma inevitably becomes resistant and comes roaring back.
@melanomapatientnetworkeuro7910
@melanomapatientnetworkeuro7910 10 жыл бұрын
I disagree. Patients with fast-growing BRAF positive tumours might have not have the time to respond to Ipilimumab and anti-PD1 antibodies are currently not readily available first-line. IL-2 is not widely used in Europe and comes with an undesirable side effect profile. The therapeutical approach therefore needs to be tailored to the specific patient's situation and an initial salvage therapy with BRAF/MEK inhibition might provide a much better starting point for immunotherapy- giving a patient the chance to profit from the latter's long-term benefits. We need smart, undogmatic approaches how to play to the strengths of the different therapeutical groups and how to mitigate their shortcomings- like the onset of resistance with targeted therapy and the lag until first benefit associated with immunotherapies. Melanoma has the dubious honour of being one the most heterogeneous and genetically instable cancers making one-size-fits-all therapeutical approaches very unlikely to work.